News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
828,800 Results
Type
Article (85504)
Company Profile (743)
Press Release (742553)
Section
Business (232200)
Career Advice (4100)
Deals (39638)
Drug Delivery (112)
Drug Development (90613)
Employer Resources (194)
FDA (17971)
Job Trends (17264)
News (395479)
Policy (39612)
Tag
Academia (2975)
Alliances (56406)
Alzheimer's disease (1316)
Approvals (17867)
Artificial intelligence (135)
Bankruptcy (394)
Best Places to Work (12441)
Biotechnology (506)
Breast cancer (111)
Cancer (958)
Cardiovascular disease (86)
Career advice (3510)
Cell therapy (223)
Clinical research (71150)
Collaboration (344)
Compensation (161)
COVID-19 (2791)
Data (849)
Diabetes (142)
Diagnostics (6627)
Drug pricing (100)
Earnings (93974)
Employer resources (166)
Events (126008)
Executive appointments (253)
FDA (18417)
Funding (302)
Gene therapy (170)
GLP-1 (670)
Government (5038)
Healthcare (20693)
Infectious disease (2872)
Inflammatory bowel disease (114)
Interviews (807)
IPO (17558)
Job creations (5177)
Job search strategy (2853)
Layoffs (483)
Legal (10036)
Lung cancer (170)
Manufacturing (170)
Medical device (14374)
Medtech (14379)
Mergers & acquisitions (22056)
Metabolic disorders (412)
Neuroscience (1580)
NextGen Class of 2024 (7652)
Non-profit (5062)
Northern California (1198)
Obesity (244)
Opinion (240)
Patents (102)
People (64000)
Pharmaceutical (146)
Phase I (21870)
Phase II (30881)
Phase III (23319)
Pipeline (204)
Postmarket research (3539)
Preclinical (9886)
Radiopharmaceuticals (256)
Rare diseases (202)
Real estate (7371)
Regulatory (25856)
Research institute (2639)
Resumes & cover letters (648)
Southern California (1088)
Startups (4274)
United States (12426)
Vaccines (634)
Weight loss (205)
Date
Today (187)
Last 7 days (897)
Last 30 days (3223)
Last 365 days (38858)
2024 (32467)
2023 (42566)
2022 (53928)
2021 (58726)
2020 (57671)
2019 (51341)
2018 (39125)
2017 (37192)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1265)
Arizona (222)
Asia (49211)
Australia (8671)
California (2838)
Canada (1172)
China (217)
Colorado (124)
Connecticut (133)
Europe (112670)
Florida (391)
Georgia (107)
Illinois (382)
Indiana (195)
Kansas (102)
Maryland (556)
Massachusetts (2378)
Michigan (160)
Minnesota (271)
New Jersey (851)
New York (854)
North Carolina (790)
Northern California (1198)
Ohio (131)
Pennsylvania (756)
South America (1647)
Southern California (1088)
Texas (410)
Washington State (354)
There are 828,800 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoff Tracker
Compass Pathways to Lay Off 30% of Employees
Follow along as
BioSpace
keeps you up-to-date on the latest pharma and biotech layoffs.
October 31, 2024
·
173 min read
·
BioSpace Editorial Staff
Layoffs
Compass Delays Pivotal Trial Readouts for Psilocybin in Depression, Lays Off 30% of Staff
In another delay for the psychedelic treatment space, Compass Pathways announced adjusted timelines for two Phase III trials of its psilocybin to address treatment-resistant depression.
October 31, 2024
·
2 min read
·
Heather McKenzie
FDA Tracker
Novartis Wins First-Line Nod for Scemblix in Certain CML Patients
In 2023, the FDA greenlit 55 new drugs and 34 cell and gene therapies. Follow along as
BioSpace
keeps you up to date on all of the FDA’s decisions in 2024.
October 31, 2024
·
196 min read
·
Heather McKenzie
Earnings
Merck Lowers Full-Year Sales Guidance Despite Strong Overall Q3 Results
Offsetting Merck’s growth in the third quarter were disappointing revenues from its HPV vaccine Gardasil and type 2 diabetes pill Januvia, with the company on Thursday narrowing its 2024 sales and adjusted profit outlooks.
October 31, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
October 31, 2024
·
3 min read
Press Releases
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024
·
14 min read
Press Releases
Repligen to Report Third Quarter 2024 Financial Results
October 31, 2024
·
4 min read
Press Releases
Standard BioTools to Participate in Upcoming Investor Conferences
October 31, 2024
·
1 min read
Press Releases
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024
October 31, 2024
·
3 min read
Press Releases
MaxCyte to Participate in Two Upcoming Investor Conferences
October 31, 2024
·
1 min read
1 of 82,880
Next
